• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amarin Corporation plc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    4/9/25 7:35:08 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email
    8-K
    0000897448falseAMARIN CORP PLC\UK00-000000000008974482025-04-092025-04-09

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): April 9, 2025

    Amarin Corporation plc

    (Exact name of registrant as specified in its charter)

     

     

    England and Wales

    0-21392

    Not applicable

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

    8th Floor, One Central Plaza, Dame Street,

    Dublin 2, Co. Dublin, D02 K7K5, Ireland

    Not applicable

    (Address of principal executive offices)

    (Zip Code)

    Registrant’s telephone number, including area code: + 353 1 6699 020

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading
    Symbol

    Name of each exchange
    on which registered

    American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc

    AMRN

    Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 3.03 Material Modification to Rights of Security Holders.


    On April 9, 2025, Amarin announced it will effect the previously announced adjustment in its ratio of its American depositary shares (“
    ADSs”) to its ordinary shares, £0.50 par value per share (“Ordinary Shares”) from one (1) ADS representing one (1) Ordinary Share to one (1) ADS representing twenty (20) Ordinary Shares (the “ADS Ratio Change”) on April 11, 2025 (the “Effective Date”). The ADS Ratio Change will result in a one for twenty reverse split of issued and outstanding ADSs, and it will have no effect on the Ordinary Shares.

    As a result of the ADS Ratio Change, the trading price of Amarin's ADSs is expected to increase proportionally, but Amarin can give no assurance that the trading price per ADS after the ADS Ratio Change will be equal to or greater than twenty (20) times the trading price per ADS before the change.

    Item 7.01 Regulation FD

    On April 9, 2025, Amarin issued a press release announcing the effective date of the ADS Ratio Change. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 7.01 and the attached Exhibit 99.1 are being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing of Amarin under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    99.1

    Press release, dated April 9, 2025 (furnished herewith).

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    * * *

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: April 9, 2025

     

    Amarin Corporation plc

     

     

     

     

    By:

    /s/ Aaron Berg

     

     

     

    Aaron Berg

    President and Chief Executive Officer

     

     


    Get the next $AMRN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Amarin

      JP Morgan resumed coverage of Amarin with a rating of Underweight

      11/20/23 7:16:51 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin downgraded by Jefferies with a new price target

      Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

      10/25/23 6:25:52 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin upgraded by Jefferies with a new price target

      Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

      1/6/23 7:26:32 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Berg Aaron bought $102,400 worth of Ordinary Shares (160,000 units at $0.64), increasing direct ownership by 25% to 805,380 units (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      8/5/24 5:30:03 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Holt Patrick bought $15,724 worth of Ordinary Shares (14,426 units at $1.09), increasing direct ownership by 5% to 314,426 units (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      1/24/24 4:31:21 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Berg Aaron converted options into 75,000 units of American Depositary Share and covered exercise/tax liability with 38,363 units of American Depositary Share, increasing direct ownership by 83% to 80,714 units (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      6/30/25 9:30:04 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cohen Paul converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:12 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sullivan Diane E. converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:07 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    SEC Filings

    See more
    • Amendment: Amarin Corporation plc filed SEC Form 8-K: Leadership Update

      8-K/A - AMARIN CORP PLC\UK (0000897448) (Filer)

      7/2/25 8:00:28 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Corporation plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

      6/24/25 7:05:28 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Corporation plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

      5/15/25 5:00:11 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

      DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2025 results and recent strategic steps followed by Q&A on Wednesday, July 30th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's second quarter 2025 financial results in the pre-market hours on July 30th. Conference Call and Webcast Information:  Access to the live call: Go to the investor relations section of the Company's website at www.amarincorp.com Dial in within the Unite

      7/23/25 7:30:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan

      Vascepa is now available to more than 95% of Canadians who are eligible and covered by a public plan or private insuranceTORONTO, July 2, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the province of Nova Scotia, for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Nova Scotia Pharmacare is effective July 1, 2025. Under the terms of the PLA, Vascepa will be reimbursed as an exception status product by the Nova Scotia formulary for th

      7/2/25 6:30:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

      -- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation (NASDAQ:AMRN) today announced that the Company has entered into an exclusive long-term license and supply agreement (the "Agreement") with Recordati S.p.A. ("Recordati") to commercialize VAZKEPA® (icosapent ethyl) across 59 countries, focused in Europe. This Agreement capitalizes on the early-stage success of VAZKEPA in Europe by partn

      6/24/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

      4/7/25 7:30:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Appoints Peter Fishman Chief Financial Officer

      DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

      12/13/24 9:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Board of Directors Announces CEO Transition

      -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

      6/4/24 7:30:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amarin Corporation plc (Amendment)

      SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

      12/8/23 4:26:23 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

      SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

      12/5/23 7:30:10 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

      SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

      9/5/23 4:15:30 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Financials

    Live finance-specific insights

    See more
    • Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

      DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2025 results and recent strategic steps followed by Q&A on Wednesday, July 30th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's second quarter 2025 financial results in the pre-market hours on July 30th. Conference Call and Webcast Information:  Access to the live call: Go to the investor relations section of the Company's website at www.amarincorp.com Dial in within the Unite

      7/23/25 7:30:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

      -- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation (NASDAQ:AMRN) today announced that the Company has entered into an exclusive long-term license and supply agreement (the "Agreement") with Recordati S.p.A. ("Recordati") to commercialize VAZKEPA® (icosapent ethyl) across 59 countries, focused in Europe. This Agreement capitalizes on the early-stage success of VAZKEPA in Europe by partn

      6/24/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Reports First Quarter 2025 Financial Results

      -- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the first quarter of 2025. "As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the glo

      5/7/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care